Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 2492423-29-5
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of molnupiravir during breastfeeding. Breastfeeding is not recommended during treatment and for 4 days after the last dose of molnupiravir.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Molnupiravir
CAS Registry Number
2492423-29-5
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Lovastatin.[Drugs and Lactation Database (...]Review Lovastatin.. Drugs and Lactation Database (LactMed®). 2006
- Unraveling the stability of plasma proteins upon interaction of synthesized uridine products: biophysical and molecular dynamics approach.[J Biomol Struct Dyn. 2020]Unraveling the stability of plasma proteins upon interaction of synthesized uridine products: biophysical and molecular dynamics approach.Dubey S, Madana SK, Kallubai M, Sarkar A, Subramanyam R. J Biomol Struct Dyn. 2020 Apr; 38(7):1927-1937. Epub 2019 May 30.
- Review Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.[Viruses. 2022]Review Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.Yip AJW, Low ZY, Chow VTK, Lal SK. Viruses. 2022 Jun 20; 14(6). Epub 2022 Jun 20.
- Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.[Antibiotics (Basel). 2021]Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.Lee CC, Hsieh CC, Ko WC. Antibiotics (Basel). 2021 Oct 23; 10(11). Epub 2021 Oct 23.
- Studies on the constituents of Broussonetia species X. Six new alkaloids from Broussonetia kazinoki Sieb.[Chem Pharm Bull (Tokyo). 2001]Studies on the constituents of Broussonetia species X. Six new alkaloids from Broussonetia kazinoki Sieb.Tsukamoto D, Shibano M, Kusano G. Chem Pharm Bull (Tokyo). 2001 Nov; 49(11):1487-91.
- Molnupiravir - Drugs and Lactation Database (LactMed®)Molnupiravir - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...